Here are four updates in spine and orthopedic biologics since Nov. 6.
1. Xtant Medical’s CollagenX wound healing product is out in a full commercial launch. CollagenX can be used by cases that Xtant Medical’s spine and orthopedics biologics portfolio addresses along with other cases across specialties.
2. The American Academy of Orthopaedic Surgeons has established the AAOS Orthobiologics Registry to measure the long-term safety, efficacy and outcomes
3. Xtant Medical released its nanOss Strata synthetic bone graft in a commercial launch. The bone graft is manufactured from hydroxycarbonapatite, which is more soluble than traditional hydroxyapatite. The bone graft is designed to more colosely mimic the structure of the human bone and increase the graft’s surface area.
4. A 24-month study of Cerapedics’ PearlMatrix P-15 peptide enhanced bone graft found it had better time-to-fusion and clinical success than a local autograft. The controlled IDE study included 293 patients across 33 U.S. sites. The study evaluated PearlMatrix in single-level transforaminal lumbar interbody fusion for adults with degenerative disc disease. At 24 months after surgery PearlMatrix met the primary endpoint of Composite Clinical Success and had statistical superiority compared to a local autograft. It was also associated with higher fusion rates compared to local autograft at 24 months.
